<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="2992">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on October 07, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04322344</url>
  </required_header>
  <id_info>
    <org_study_id>covid-19 add-on therapy</org_study_id>
    <nct_id>NCT04322344</nct_id>
  </id_info>
  <brief_title>Escin in Patients With Covid-19 Infection</brief_title>
  <acronym>add-on-COV2</acronym>
  <official_title>Efficacy and Safety of Escin as add-on Treatment in Covid-19 Infected Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Catanzaro</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Azienda Ospedaliera Pugliese Ciaccio</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Azienda Ospedaliera Policlinico &quot;Mater Domini&quot;</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Catanzaro</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      In December 2019,a new type of pneumonia caused by the coronavirus (COVID-2019) broke out in
      Wuhan ,China, and spreads quickly to other Chinese cities and 28 countries. More than 70000
      people were infected and over 2000 people died all over the world. There is no specific drug
      treatment for this disease. Considering that lung damage is related to both viral infection
      and burst of cytokines, our idea is to evaluate the efficacy and safety of escin as add-on
      treatment to conventional antiviral drugs in COVID-19 infected patients.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">March 23, 2020</start_date>
  <completion_date type="Anticipated">December 30, 2020</completion_date>
  <primary_completion_date type="Actual">June 30, 2020</primary_completion_date>
  <phase>Phase 2/Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Supportive Care</primary_purpose>
    <masking>Double (Participant, Care Provider)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Mortality rate</measure>
    <time_frame>up to 30 days</time_frame>
    <description>All cause mortality</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Clinical status evaluated in agreement with guidelines</measure>
    <time_frame>up to 30 days</time_frame>
    <description>mild type：no No symptoms, Radiological examination: no pneumonia; possible mild increase in C-reactive portein 2, moderate type: fever, cough, or other respiratory symptoms. Radiological examination: pneumonia, SpO2&gt;93% without oxygen inhalation ; increase in C reactive protein, 3: severe type: a. Rate ≥30bpm；b. Pulse Oxygen Saturation (SpO2)≤93% without oxygen inhalation，c. PaO2/FiO2(fraction of inspired oxygen )≤300mmHg ；4. Critically type：match any of the follow: a. need mechanical ventilation; b. shock; c. (multiple organ dysfunction syndrome) MODS</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>The differences in oxygen intake methods</measure>
    <time_frame>up to 30 days</time_frame>
    <description>Pulse Oxygen Saturation(SpO2)&gt;93%，1. No need for supplemental oxygenation; 2. nasal catheter oxygen inhalation（oxygen concentration%,The oxygen flow rate：L/min）；3. Mask oxygen inhalation（oxygen concentration%,The oxygen flow rate：L/min）；4. Noninvasive ventilator oxygen supply（Ventilation mode,oxygen concentration%,The oxygen flow rate：L/min,）；5. Invasive ventilator oxygen supply（Ventilation mode,oxygen concentration%,The oxygen flow rate：L/min,）</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time of hospitalization (days)</measure>
    <time_frame>up to 30 days</time_frame>
    <description>days</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time of hospitalization in intensive care units</measure>
    <time_frame>up to 30 days</time_frame>
    <description>days</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pulmonary function</measure>
    <time_frame>up to 3 months after discharge</time_frame>
    <description>forced expiratory volume at one second ,maximum voluntary ventilation at 1month，2month，3month after discharge</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">120</enrollment>
  <condition>Coronavirus Infections</condition>
  <arm_group>
    <arm_group_label>oral escin group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Standard therapy+Escin tablet 40mg*3, os for 12 days</description>
  </arm_group>
  <arm_group>
    <arm_group_label>control group</arm_group_label>
    <arm_group_type>Sham Comparator</arm_group_type>
    <description>standard therapy</description>
  </arm_group>
  <arm_group>
    <arm_group_label>parenteral escin group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>standard treatment + sodium Escinate 20mg iv/day for 12 days</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Escin</intervention_name>
    <description>treatment with escin or escinate sodium</description>
    <arm_group_label>oral escin group</arm_group_label>
    <arm_group_label>parenteral escin group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>standard therapy</intervention_name>
    <description>antiviral drugs</description>
    <arm_group_label>control group</arm_group_label>
    <arm_group_label>oral escin group</arm_group_label>
    <arm_group_label>parenteral escin group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Aged between 18 and 75 years, extremes included, male or female

          -  Positivity to covid-19 screening test in molecular biology

          -  In escin group: Low response to standard treatment

          -  Ability to understand and the willingness to sign a written informed consent document

        Exclusion Criteria:

          -  Female subjects who are pregnant or breastfeeding.

          -  patients with previous history to allergy

          -  patients meet the contraindications of escin

          -  Patients have any condition that in the judgement of the Investigators would make the
             subject inappropriate for entry into this study.

          -  patients can't take drugs orally
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>LUCA GALLELLI</last_name>
    <phone>3339245656</phone>
    <phone_ext>3339245656</phone_ext>
    <email>gallelli@unicz.it</email>
  </overall_contact>
  <location>
    <facility>
      <name>Luca Gallelli</name>
      <address>
        <city>Catanzaro</city>
        <zip>88100</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>LUCA GALLELLI</last_name>
      <phone>3339245656</phone>
      <phone_ext>3339245656</phone_ext>
      <email>gallelli@unicz.it</email>
    </contact>
  </location>
  <location_countries>
    <country>Italy</country>
  </location_countries>
  <verification_date>September 2020</verification_date>
  <study_first_submitted>March 23, 2020</study_first_submitted>
  <study_first_submitted_qc>March 23, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">March 26, 2020</study_first_posted>
  <last_update_submitted>September 11, 2020</last_update_submitted>
  <last_update_submitted_qc>September 11, 2020</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 15, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Catanzaro</investigator_affiliation>
    <investigator_full_name>Luca Gallelli</investigator_full_name>
    <investigator_title>Clinical Professor</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Infection</mesh_term>
    <mesh_term>Coronavirus Infections</mesh_term>
    <mesh_term>Severe Acute Respiratory Syndrome</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

